TABLE 4.
Subjects | No. of pts | Intervention | Dose (GBq) | Cycles | Tumor response |
mPFS (months) | Other main results/conclusions | References | |||
CR | PR | SD | PD | ||||||||
Recurrent or progressive Ms | 5 | 177Lu-octreotate | 14.8–29.6 | 2–4 | 0 | 0 | 2 | 3 | NA | 177Lu-octreotate can have therapeutic effects in meningioma. | (99) |
Progressive Ms | 20 | 177Lu-DOTATATE 90Y-DOTATOC | 13.7–27.6 | 1–4 | 0 | 0 | 10 | 10 | 5.4 | PFS6 was 42%; treatment was well tolerated. | (100) |
Recurrent or progressive Ms | 15 | 90Y-DOTATOC | 1.35–14.8 | 2–4 | 0 | 0 | 13 | 2 | 24 | Toxicity was moderate. | (101) |
Progressive unresectable Ms | 34 | 177Lu-DOTATATE 90Y-DOTATOC | 1.5–22.2 | 1–4 | 0 | 0 | 23 | 11 | NA | The mean survival 8.6 years; treatment was well tolerated, | (102) |
Recurrent Ms | 29 | 90Y-DOTATOC | 5–15 | 2–6 | 0 | 0 | 19 | 10 | 21 | Median OS was 40 months; treatment was well tolerated. | (103) |
Recurrent Ms | 8 | 111In-Pentetreotide | 4.8–29 | 2–4 | 0 | 2 | 5 | 1 | NA | Treatment was well tolerated. | (104) |
Advanced symptomatic Ms | 10 | EBRT + 177Lu-DOTATATE or DOTATOC | 7.0–7.9 | 1 | 1 | 1 | 8 | 0 | 13.4 | The combination treatment was safe and effective. | (105) |
CR = complete response; DOTATOC = DOTA-(Tyr3)-octreotide; DOTATATE = DOTA-D-Phe1-Tyr3-octreotate;EBRT = External beam radiotherapy; 111In = 111-Indium; 177Lu = 177-Lutetium; mPFS = median progression survival; Ms = meningiomas; NA = not-available; OS = overall survival; PD = progressive disease; PFS6 = 6 months progression survival; PR = partial response; Pts = patients; SD = stable disease; 90Y = 90-Yttrium.